Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TO_AITION

Financiado

Cerrado

A high dimensional approach for unwinding immune metabolic causes of cardiovascu...

A high dimensional approach for unwinding immune metabolic causes of cardiovascular disease depression multimorbidities Depression is a common and serious comorbidity of cardiovascular disease (CVD) affecting one in three patients, among which women earlier and more frequently. Depression increases the risk for CVD development, acute events and mor... ver más

31/12/2024

BIOMEDICAL RESEARC...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHI... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-12-31

SC1-BHC-01-2019: Understanding causative mechanisms...

I+D

Cerrada hace 6 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

BIOMEDICAL RESEARCH FOUNDATI...

879.34K€ | Lider

STICHTING AMSTERDAM UMC

429.68K€ | Participante

PIRKANMAAN HYVINVOINTIALUE

526.40K€ | Participante

LODZ

252.00K€ | Participante

Proyectos interesantes

REPROGRAM

Medical Technol...

Data Science

6M€ Cerrado

EarlyCause

Medical Technol...

Data Science

6M€ Cerrado

BIOMENDELIAN

Medical Technol...

Data Science

2M€ Cerrado

METSGENES

Medical Technol...

Data Science

224K€ Cerrado

GENTRECAD

Medical Technol...

Data Science

171K€ Cerrado

CoMorMent

Medical Technol...

Data Science

6M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 60 meses Fecha Inicio: 2019-12-06
Fecha Fin: 2024-12-31

Líder del proyecto

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHI... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Depression is a common and serious comorbidity of cardiovascular disease (CVD) affecting one in three patients, among which women earlier and more frequently. Depression increases the risk for CVD development, acute events and mortality by >2 fold, independently of traditional risk factors, and constitutes an enormous socioeconomic burden in terms of morbidity, mortality and healthcare costs. Still, the patients at risk, disease trajectories and causative mechanisms involved remain unknown. TO_AITION addresses the hypothesis that immune-metabolic dysregulation, occurring as a result of genetic, lifestyle and environmental risk factors ‘training’ innate immunity, drives low grade systemic inflammation leading to the development of CVD-depression comorbidity. It integrates basic (cell models, immune-metabolic mechanisms, myeloid cell reprogramming), preclinical (animal models, CRISPR genome editing) and clinical (longitudinal cohorts with comprehensive existing data) research, in order to characterise immune-metabolic mechanisms driving CVD-depression comorbidity. Both hypothesis and data-driven strategies will be employed to address causality, focusing on genetic, epigenetic, transcriptional, metabolic and other disturbances leading to the development of comorbidity. Drug-drug interactions and their effects on causative mechanisms and disease trajectories will also be determined. Pathways identified will be evaluated in cell-based and animal models to prove their causal role and obtain mechanistic insight. Finally, new risk models will be developed, and relevant regulatory, cost-effectiveness and feasibility issues addressed. Effective patient-oriented awareness actions, dissemination, exploitation and management activities are also provisioned. TO_AITION will therefore rationally change our current understanding of the causative mechanisms driving CVD-depression comorbidity, unravelling patients’ complexity and improving their diagnosis, monitoring and management.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores